Answers are grounded in this paper and cite their sources.
Background Cardiac surgery is associated with severe acute postoperative pain. The erector spinae plane (ESP) block has been reported to provide effective analgesia following cardiac surgery; however, evidence supporting ESP compared with traditional parenteral analgesia remains conflicting. This meta-analysis compares the analgesic effectiveness of single injection and continuous ESP to parenteral analgesia (Control) in adult patients undergoing cardiac surgery. Methods Randomized trials were identified that compared the analgesic effectiveness of single injection or continuous ESP to Control in patients undergoing cardiac surgery. The primary outcome was rest-pain severity at 24 hours postoperatively. Secondary outcomes included rest pain at 0, 6, and 12 hours; analgesic consumption at 24 hours in milligrams of oral morphine; time to first analgesic request; time to extubation; duration of hospital stay; duration of intensive care unit stay; and block- and opioid-related side effects. Statistical pooling was conducted using the Hartung-Knapp-Sidik-Jonkman (HKSJ) method for random effects. Results A total of 27 trials, encompassing 1963 patients, were included. When compared with Control, single injection- and continuous-ESP did not improve VAS rest pain severity at 24 hours, with a mean difference (MD) (HKSJ 95% CI) of −0.46 cm (−1.14 to 0.22) (p=0.167, I2=95% (92% to 96%)) and −0.65 cm (−1.41 to 0.11) (p=0.080, I2=91% (83% to 95%)), respectively. The 95% prediction interval was observed to be −3.02 cm to 2.09 cm and −2.55 cm to 1.25 cm for the single-injection- and continuous-ESP comparisons, respectively. For rest pain at 24 hours, the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) quality of evidence was rated as low for the single-injection comparison, and very low for the continuous-ESP comparison. Similar results were observed when assessing analgesic consumption at 24 hours when single-injection ESP was compared with control, with an MD (HKSJ 95% CI) of -38.95 mg (−78.98 to 1.08) (p=0.055, I2=99% (99% to 99%)). In contrast, continuous ESP appeared to improve analgesic consumption at 24 hours by an MD (HKSJ 95% CI) of -26.15 mg (−51.44 to −0.86) (p=0.045, I2=88% (75% to 94%)). The 95% prediction interval was observed to be −107.52 mg to 29.62 mg and −97.58 mg to 45.28 mg for the single-injection- and continuous-ESP comparisons, respectively. For 24-hour opioid consumption, the GRADE quality of evidence was rated as very low for both comparisons. Conclusions In adult patients undergoing cardiac surgery, low to very low certainty of evidence suggests that neither single-injection nor continuous ESP block provides clinically meaningful improvements in postoperative pain severity or opioid consumption at 24 hours compared with parenteral analgesia alone. Single-injection ESP may offer modest, short-term analgesic benefits during the early postoperative period, but these effects are transient and not sustained. Overall, the findings do not support the routine use of ESP for durable postoperative analgesia following cardiac surgery; however, the heterogeneity of results calls for cautious interpretation. PROSPERO registration number CRD420251149441.
No takes yet. Share an insight, caveat, or question.
Hussain et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: